Clinical Trials

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts

452 enrolled 16 charts 1 FDA

Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

39 enrolled 26 charts

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

No longer available

DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02139592 2020-07-13

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Completed

292 enrolled 39 charts

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT01309789 2017-06-28

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

39 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00866047 2017-03-22

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

58 enrolled 19 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00947856 2017-02-02

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

110 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00079755 2014-12-18

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

80 enrolled

Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT00430846 2014-12-18

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

45 enrolled

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Phase 1 Terminated

44 enrolled

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

73 enrolled

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

NCT01026233 2014-12-12

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

52 enrolled